Feedback / Questions
izokibep (ABY-035) - Affibody, ACELYRIN
https://www.prnewswire.com/news-releases/acelyrin-inc-announces-300-million-series-c-financing-to-accelerate-phase-3-development-of-izokibep-a-unique-il-17a-inhibitor-to-treat-inflammatory-diseases-301622338.html
Sep 13, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next